Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
Stephen E. Gitelman, Brian N. Bundy, Ele Ferrannini, et al.
The Lancet Diabetes & Endocrinology (2021) Vol. 9, Iss. 8, pp. 502-514
Open Access | Times Cited: 91

Showing 1-25 of 91 citing articles:

Phenotypic drug discovery: recent successes, lessons learned and new directions
Fabien Vincent, Arsenio Nueda, Jonathan Lee, et al.
Nature Reviews Drug Discovery (2022) Vol. 21, Iss. 12, pp. 899-914
Open Access | Times Cited: 193
Teplizumab and β-Cell Function in Newly Diagnosed Type 1 Diabetes
Eleanor L. Ramos, Colin Dayan, Lucienne Chatenoud, et al.
New England Journal of Medicine (2023) Vol. 389, Iss. 23, pp. 2151-2161
Closed Access | Times Cited: 100
The immunology of type 1 diabetes
Kevan C. Herold, Thomas Delong, Ana Luisa Perdigoto, et al.
Nature reviews. Immunology (2024) Vol. 24, Iss. 6, pp. 435-451
Open Access | Times Cited: 47
Semaglutide in Early Type 1 Diabetes
Paresh Dandona, Ajay Chaudhuri, Husam Ghanim
New England Journal of Medicine (2023) Vol. 389, Iss. 10, pp. 958-959
Closed Access | Times Cited: 44
Partners in Crime: Beta-Cells and Autoimmune Responses Complicit in Type 1 Diabetes Pathogenesis
Eliana Toren, KaLia S. Burnette, Ronadip R. Banerjee, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 71
Causal associations between type 1 diabetes mellitus and cardiovascular diseases: a Mendelian randomization study
Zirui Liu, Haocheng Wang, Zhengkai Yang, et al.
Cardiovascular Diabetology (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 31
C-peptide and metabolic outcomes in trials of disease modifying therapy in new-onset type 1 diabetes: an individual participant meta-analysis
Peter Taylor, Kimberly S. Collins, Anna Lam, et al.
The Lancet Diabetes & Endocrinology (2023) Vol. 11, Iss. 12, pp. 915-925
Open Access | Times Cited: 24
Evidence for C-Peptide as a Validated Surrogate to Predict Clinical Benefits in Trials of Disease-Modifying Therapies for Type 1 Diabetes
Esther Latres, Carla J. Greenbaum, Maria L. Oyaski, et al.
Diabetes (2024) Vol. 73, Iss. 6, pp. 823-833
Closed Access | Times Cited: 10
An accomplice more than a mere victim: The impact of β-cell ER stress on type 1 diabetes pathogenesis
Gulcan Semra Sahin, Hugo Lee, Feyza Engin
Molecular Metabolism (2021) Vol. 54, pp. 101365-101365
Open Access | Times Cited: 51
Adult-onset autoimmune diabetes
Raffaella Buzzetti, Ernesto Maddaloni, Jason L. Gaglia, et al.
Nature Reviews Disease Primers (2022) Vol. 8, Iss. 1
Open Access | Times Cited: 34
Pharmacological inhibitors of β-cell dysfunction and death as therapeutics for diabetes
Stéphane Dalle, Amar Abderrahmani, Éric Renard
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 16
Exercise as a non-pharmacological intervention to protect pancreatic beta cells in individuals with type 1 and type 2 diabetes
Alexandra Coomans de Brachène, Corentin Scoubeau, Anyishaï Musuaya, et al.
Diabetologia (2022) Vol. 66, Iss. 3, pp. 450-460
Open Access | Times Cited: 25
Disease-modifying therapies and features linked to treatment response in type 1 diabetes prevention: a systematic review
Jamie L. Felton, Kurt Griffin, Richard A. Oram, et al.
Communications Medicine (2023) Vol. 3, Iss. 1
Open Access | Times Cited: 15
Inhibition of polyamine biosynthesis preserves β cell function in type 1 diabetes
Emily K. Sims, Abhishek Kulkarni, Audrey Hull, et al.
Cell Reports Medicine (2023) Vol. 4, Iss. 11, pp. 101261-101261
Open Access | Times Cited: 15
Islet autoimmunity in human type 1 diabetes: initiation and progression from the perspective of the beta cell
Peter J. Thompson, Jasmine Pipella, Guy A. Rutter, et al.
Diabetologia (2023) Vol. 66, Iss. 11, pp. 1971-1982
Open Access | Times Cited: 13
GDF15 Protects Insulin-Producing Beta Cells against Pro-Inflammatory Cytokines and Metabolic Stress via Increased Deamination of Intracellular Adenosine
Anongnad Ngamjariyawat, Jing Cen, Xuan Wang, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 2, pp. 801-801
Open Access | Times Cited: 5
Can fecal microbiota transplantations modulate autoimmune responses in type 1 diabetes?
Coco M. Fuhri Snethlage, Douwe de Wit, Koen Wortelboer, et al.
Immunological Reviews (2024) Vol. 325, Iss. 1, pp. 46-63
Closed Access | Times Cited: 5
The β-Cell in Type 1 Diabetes Pathogenesis: A Victim of Circumstances or an Instigator of Tragic Events?
Roberto Mallone, Clémentine Halliez, Jinxiu Rui, et al.
Diabetes (2022) Vol. 71, Iss. 8, pp. 1603-1610
Open Access | Times Cited: 20
TNF-α inhibitors for type 1 diabetes: exploring the path to a pivotal clinical trial
Cassandra Bazile, Magdy M Abdel Malik, Courtney Ackeifi, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 4
Autoimmune Type 1 Diabetes: An Early Approach Appraisal for Spain by the AGORA Diabetes Collaborative Group
Fernando Gómez-Peralta, Pedro J. Pinés-Corrales, Estefanía Santos, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 2, pp. 418-418
Open Access
Disease-modifying strategies: Targeting protein kinases in multiple sclerosis and other autoimmune disorders
Franz Felix Konen, Nora Möhn, Torsten Witte, et al.
Autoimmunity Reviews (2025) Vol. 24, Iss. 4, pp. 103754-103754
Closed Access
Disease-modifying pharmacological treatments of type 1 diabetes (T1D): Molecular mechanisms, target checkpoints and possible combinatorial treatments.
Liudmila Kosheleva, Daniil S. Koshelev, Francisco Alejandro Lagunas‐Rangel, et al.
Pharmacological Reviews (2025) Vol. 77, Iss. 2, pp. 100044-100044
Closed Access
A Cure for Type 1 Diabetes: Are We There Yet?
Christian P. Schaaf, Lori Sussel
Diabetes Technology & Therapeutics (2025)
Closed Access
Insulin Secretion and Insulin Sensitivity Change in Different Stages of Adult-Onset Type 1 Diabetes: A Cross-Sectional Study
Tanja Miličić, Aleksandra Jotić, Katarina Lalić, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 4, pp. 1109-1109
Open Access
Immunotherapy as a treatment for type 1 diabetes mellitus in children and young adults: A comprehensive systematic review and meta-analysis
G. Salame, Vincent Hakim, Chebly Dagher, et al.
PLoS ONE (2025) Vol. 20, Iss. 4, pp. e0321727-e0321727
Open Access
Page 1 - Next Page

Scroll to top